Vanda Pharmaceuticals (VNDA) Change in Cash (2010 - 2026)

Vanda Pharmaceuticals has reported Change in Cash for 17 years, with the latest figure at -$30.8 million in Q1 2026.

• Quarterly Change in Cash fell 425.07% year-over-year to -$30.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$57.8 million (down 332.29% YoY) and the FY2025 annual result came in at -$17.5 million, up 47.87% from the prior year.
• Change in Cash declined to -$30.8 million in Q1 2026 per VNDA's latest filing, from $14.8 million in the prior quarter.
• Over five years, Change in Cash peaked at $219.1 million in Q1 2023 and troughed at -$204.1 million in Q2 2023.
• A 5-year average of $112529.4 and a median of -$8.7 million in 2022 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2023: Change in Cash jumped 5428.21% in 2022, then tumbled 2245.63% in 2023.
• Over 5 years, Change in Cash stood at $85.6 million in 2022, then slumped by 155.31% to -$47.4 million in 2023, then soared by 103.84% to $1.8 million in 2024, then soared by 715.23% to $14.8 million in 2025, then sank by 307.82% to -$30.8 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered -$30.8 million, $14.8 million, and -$11.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.